PCI noninferior to CABG for left main coronary artery disease

November 1, 2016

(HealthDay)—For patients with left main coronary artery disease, percutaneous coronary intervention (PCI) with everolimus-eluting stents is noninferior to coronary artery bypass grafting (CABG), according to a study published online Oct. 31 in the New England Journal of Medicine. The research was published to coincide with the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics 2016 meeting, held from Oct. 29 to Nov. 2 in Washington, D.C.

Gregg W. Stone, M.D., from New York Presbyterian Hospital in New York City, and colleagues randomized 1,905 patients with left main of low or intermediate anatomical complexity to undergo PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents (948 patients) or CABG (957 patients).

The researchers found that a primary end point (rate of a composite of death from any cause, stroke, or myocardial infarction at three years) had occurred in 15.4 and 14.7 percent of patients in the PCI and CABG groups, respectively (difference, 0.7 percentage points; P = 0.02 for noninferiority; hazard ratio, 1.00; 95 percent confidence interval, 0.79 to 1.26; P = 0.98 for superiority). The secondary end point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9 and 7.9 percent of patients in the PCI and CABG groups, respectively (P < 0.001 for noninferiority; P = 0.008 for superiority).

"PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or at three years," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Abbott Vascular, which funded the study.

Explore further: Three-year results from the EXCEL trial presented

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Three-year results from the EXCEL trial presented

October 31, 2016

A large-scale randomized trial examining percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) in patients with left main coronary artery disease (LMCAD) and low-intermediate SYNTAX scores ...

Five-year outcomes similar for off-, on-pump CABG in CAD

October 24, 2016

(HealthDay)—Five-year outcomes are similar for patients with coronary artery disease who undergo off-pump or on-pump coronary artery bypass grafting (CABG), according to a study published online Oct. 23 in the New England ...

CABG plus optimal medical therapy best in T2DM and CAD

August 30, 2016

(HealthDay)—For patients with type 2 diabetes and coronary artery disease (CAD), coronary artery bypass grafting (CABG) plus optimal medical therapy (OMT) is superior to percutaneous coronary intervention (PCI) plus OMT, ...

Bioresorbable vascular scaffold deemed noninferior

October 13, 2015

(HealthDay)—For patients with noncomplex obstructive coronary artery disease, treatment with an everolimus-eluting bioresorbable vascular scaffold is noninferior to treatment with an everolimus-eluting cobalt-chromium stent, ...

Recommended for you

Nigeria: Clean-burning stoves improve health for new mothers

January 13, 2017

In a small clinical trial that replaced widely used biomass and kerosene cookstoves with clean-burning ethanol stoves, a team of researchers from the University of Chicago and the University of Ibadan (Nigeria) was able to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.